CMT's CannaBiz Invest Asia Summit on 29-30 August, 2019 in Bangkok, zooms in on the legal and commercial aspects of medical and industrial cannabis market in Asia vis-à-vis government regulations, investments, cultivation and value added products. With more Asian countries starting to legalise medical and industrial cannabis use, major cannabis product manufacturers will convene in Bangkok for a timely summit to share insights on this new market.Aurora Cannabis shares insights on Global Cannabis Market Outlook & Investment Landscape. Day 1 also features sessions from cannabis producers – CannAcubed presenting a case study on 'China's Industrial Hemp Cultivation & Value Chain Investment' and Elixinol Global providing the 'Growth Outlook for Hemp Foods, Protein & the CBD Market in Japan & Globally'. Coffee break sponsor – Medipharm Labs will speak on Australia's Role in APAC Medical Cannabis Market.
Other cannabis producers sharing their perspectives are:• Blue Sky Biologicals - Hemp: Beyond CBD & THC, a Whole Plant Model• Hikurangi Cannabis Company - Cannabis Legislation in New Zealand: Reflections on• Government Efforts to Design World-Leading Medicinal Cannabis & Full• Legalisation• Bombay Hemp Company Private Limited (BOHECO) - Industrial and Medical• Cannabis Investment in India – Scientific and Legal Perspective• BOL Pharma - From Farm to Pharmaceutical Products – Israel's Experience
Thailand - the first Southeast Asian country to legalise cannabis use for medical purposes – gather 2 experts providing details on – 'Understanding the Medical Cannabis InvestmentLandscape & Regulatory Hurdles in Thailand' - Tilleke & Gibbins International and 'Integration of Medical Cannabis in Thai Traditional Medicine - A Balancing Game' - Dept.of Thai Traditional and Alternative Medicine, Ministry of Health.
Organised by Centre for Management Technology (CMT), the program also features sessions on: The Future of Sustainable Fashion & Hemp Fibres Industry - Kingdom Holdings "Green Green Profits" - The Cultivation of Outdoor Medical Cannabis as a BusinessModel for Asia - Jacana Holdings Commercialisation of Plant-Derived Cannabinoid Prescription Medicines to MeetGlobal Demand - MGC Pharmaceuticals Pharmaceutical Development in Man-Made Cannabinoids - Akseera Pharma
In addition, MYM Nutraceuticals, Helius Therapeutics and Cannex Capital join a paneldiscussion on 'Accessing Capital Markets for Cannabis Investments – Options & Challenges'.Meet exhibitors Shenzhen Number Energy Saving Corporation and Blue Sky Biologicals among others at the event. For exhibition details, email [email protected]
View event website For registration or call +65 6346 9147 for more details.Contact Ms. Grace Oh [email protected] +65 6346 9147